Differentiable function

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Computational biology, Malignancy, Canadian Aviation Regulations, Gene editing, Bone disease, Cell, Hook effect, CXCR4, Enfortumab vedotin, Synthetic biology, Patient, Neoplasm, Epitope, Differentiable function, Ink, PBMC, Protein engineering, HLA, Science, Cytotoxicity, AACR, Phenotype, Therapy, IPSC, Skin, Inflammation, Prognosis, Carcinogenesis, Rejection, CD22, VHH, Poster, NK, Century, Autoimmunity, Bone marrow, Engineering, CD19, Vaccine

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.

Key Points: 
  • PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.
  • This novel CAR was engineered and tested in iPSC-derived gamma-delta T cells, showing in vitro tumor cell cytotoxicity.
  • These findings support the continued examination of a CD19xCD22 bispecific CAR for off-the-shelf allogeneic cell therapy to expand patient access beyond CD19 CAR-T cell therapies.
  • In these preclinical studies, Century identified novel single-domain antibodies (VHH) that bind to multiple epitopes on the NECTIN4 extracellular domain.

Meatable Achieves Landmark Breakthrough In Cultivated Meat Technology, Cuts Production Time To Only 4 Days

Retrieved on: 
Thursday, March 21, 2024
Supply Chain Management, Retail, Specialty, Food, Beverage, Bioreactor, Meat, Farmer, CAPEX, Cell, Environment, PSC, Differentiable function, Water, Multimedia, Animal, Movement, Agriculture

Meatable , an industry-leading food technology company, today announced that it has reached an important milestone in its efforts to produce cultivated meat at scale.

Key Points: 
  • Meatable , an industry-leading food technology company, today announced that it has reached an important milestone in its efforts to produce cultivated meat at scale.
  • This breakthrough will enable the company to produce cultivated meat significantly faster and at lower costs than industry norms, and is therefore an important step towards the commercialization of Meatable’s technology and large-scale production of cultivated meat products more broadly.
  • View the full release here: https://www.businesswire.com/news/home/20240321679210/en/
    Meatable Achieves Landmark Breakthrough In Cultivated Meat Technology, Cuts Production Time To Only 4 Days (Photo: Business Wire)
    The breakthrough, using Meatable’s core patented Opti-Ox technology, confronts the challenges faced by the cultivated meat industry to produce product fast and efficiently in order to scale to commercial levels.
  • With its process enabling movement from “cell-to-sausage” in only four days, Meatable can produce high-quality cultivated meat at a significantly reduced cost.

Induced Pluripotent Stem Cells Market Report, Featuring Historical Revenue Data for 2021 and 2022, Estimated Figures for 2023, and Compound Annual Growth Rates (CAGRs) through 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Cell, Stem cell, Fibroblast, B cell, Enzyme, Serum, Drug discovery, Row, Good manufacturing practice, Differentiable function, Neuron, GMP, Hepatocyte, Regenerative medicine, Medium (website), Antibody, Drug development, Geography, Astrocyte, IPSC, Endothelium

For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.

Key Points: 
  • For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.
  • An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.
  • The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW).
  • The report will provide details with respect to induced pluripotent stem cells.

Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024

Retrieved on: 
Tuesday, January 16, 2024
MSD, PRISM, Renal cell carcinoma, Hypoxia, Patient, HCC, Research, Neoplasm, Meta-analysis, Oxidative stress, Rescue coordination centre, RCC, Merck & Co., ASCO, Cell lineage, Everolimus, Society, Pembrolizumab, Headquarters, FGFR2, Deep, Cholangiocarcinoma, Drug discovery, Hepatocellular carcinoma, Cancer, Food, Proteostasis, CBP, Safety, Abstract, Food and Drug Administration, FDA, Inflammation, CREB-binding protein, Biomarker, LEAP, TKI, Merck, Differentiable function, Pharmaceutical industry

TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.

Key Points: 
  • TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.
  • First, the company will share findings in hepatocellular carcinoma (HCC) and cholangiocarcinoma during the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI24), which is taking place from January 18-20.
  • Tasurgratinib, for which a marketing authorization application was submitted in Japan in December 2023, is an orally available selective tyrosine kinase inhibitor of FGFR1-3.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancers.

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion

Retrieved on: 
Tuesday, December 19, 2023
Drug resistance, FGF, Drug discovery, Survival, Tumor microenvironment, FGFR2, FGFR1, Prognosis, Differentiable function, MHLW, Deep, Cholangiocarcinoma, Disease, FGFR, Cancer, Inflammation, Ministry, FGFR3, Proteostasis, Hypoxia, Oxidative stress, Patient, Safety, Eisai

TOKYO, Dec 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, "tasurgratinib") for biliary tract cancer with FGFR2 gene fusion.

Key Points: 
  • TOKYO, Dec 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, "tasurgratinib") for biliary tract cancer with FGFR2 gene fusion.
  • In Japan, tasurgratinib has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, (MHLW).
  • This application is based on the results of a multicenter, open-label, single-arm clinical phase II trial (Study 201) in Japan and China conducted by Eisai.
  • Study 201 enrolled patients with unresectable biliary tract cancer with FGFR2 gene fusion previously treated with gemcitabine-based combination chemotherapy.

Gene Expression (DNA Chip/Microarray, Kits & Reagents) Market Report 2023: Global Analysis and Forecasts by Technique, Capacity, Process, Application - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 29, 2023
Technology, Research, Genetics, Other Technology, Stem Cells, Biotechnology, Health, Other Science, Science, Gene expression, Hormone, DNA, Gene, Investment, Differentiable function, Application, Medicine, USD, Messenger, Nutrient, Genome, Budapest Metropolitan University, RNA, Capacity, Drug discovery, Growth, NGS, A-DNA, Temperature, Microarray, Process, Vaccine, Fine chemical, Agriculture

The "Gene Expression Market Size, Share & Trends Analysis Report By Product (DNA Chip/Microarray, Kits & Reagents), By Technique (Promoter Analysis, RNA Exp.

Key Points: 
  • The "Gene Expression Market Size, Share & Trends Analysis Report By Product (DNA Chip/Microarray, Kits & Reagents), By Technique (Promoter Analysis, RNA Exp.
  • ), By Capacity, By Process, By Application, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global gene expression market size is anticipated to reach USD 20.94 billion by 2030, registering a CAGR of 5.0% from 2023 to 2030.
  • In the post-genomic and epigenomic era, it is increasingly recognized that gene expression is not solely controlled by gene sequences.

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023
Research, Bristol Myers Squibb, CAR, Lymphoma, Neogene, Patent, IPSC, CD19, G&A, Inflammation, GAAP, MBA, Differentiable function, R, BMS, ASH, Pharming, Century, Research and development, Interim, Ink, Autoimmunity, Cancer, Investment, Therapy, Patient, Administration, Life insurance, Pharmaceutical industry, Management, Cryptocurrency

PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the third quarter ended September 30, 2023.

Key Points: 
  • - Ended third quarter 2023 with cash, cash equivalents, and investments of $284.3 million; Cash runway into 2026 -
    PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics , Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the third quarter ended September 30, 2023.
  • Greg Russotti, Interim Chief Executive Officer, Century Therapeutics added, “We continued to advance our Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory CD19 positive B-cell lymphomas.
  • He brings to Century over 20 years of broad-ranging global leadership experience across the healthcare industry, most recently serving as Chief Operating Officer at Neogene Therapeutics.
  • Cash Position: Cash, cash equivalents, and investments were $284.3 million as of September 30, 2023, as compared to $367.4 million as of December 31, 2022.

Kanazawa University research: Genetic switches in tumor development

Retrieved on: 
Thursday, November 9, 2023
Transition, Neoplasm, Triple test, Organoid, TGF, Colorectal cancer, Cancer, Differentiable function, Environment, Receptor (biochemistry), Growth, Malignancy, Kanazawa University, Transforming growth factor beta, Cytokine, EMT, Cancer research, Gene, Blood, Infection, Mutation, Vaccine, Medical imaging

KANAZAWA, Japan, Nov. 9, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway.

Key Points: 
  • KANAZAWA, Japan, Nov. 9, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway.
  • However, it has been established that a process known as transforming growth factor ß (TGF-ß) signaling plays a role in both tumor suppression and progression.
  • Now, Masanobu Oshima from Kanazawa University and colleagues have studied the precise genetic conditions underlying the outcome of TGF-ß signaling.
  • In certain cancer cells treated with activin, the researchers noted that the partial EMT is induced with tumor aggressiveness and development.

Kanazawa University research: Genetic switches in tumor development

Retrieved on: 
Thursday, November 9, 2023
Transition, Neoplasm, Triple test, Organoid, TGF, Colorectal cancer, Cancer, Differentiable function, Environment, Receptor (biochemistry), Growth, Malignancy, Kanazawa University, Transforming growth factor beta, Cytokine, EMT, Cancer research, Gene, Blood, Infection, Mutation, Vaccine, Medical imaging

KANAZAWA, Japan, Nov. 9, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway.

Key Points: 
  • KANAZAWA, Japan, Nov. 9, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway.
  • However, it has been established that a process known as transforming growth factor ß (TGF-ß) signaling plays a role in both tumor suppression and progression.
  • Now, Masanobu Oshima from Kanazawa University and colleagues have studied the precise genetic conditions underlying the outcome of TGF-ß signaling.
  • In certain cancer cells treated with activin, the researchers noted that the partial EMT is induced with tumor aggressiveness and development.

Geoscells Has Begun a New Phase of Stem Cells Research for Cancer Treatment

Retrieved on: 
Thursday, October 5, 2023
Health, Lionheart, Mass spectrometry, Memory, Biotechnology, Medicine, Disease, Laboratory, Cancer, Patient, Differentiable function, Research, Science, Kuna, Learning, Tissue, Neoplasm, Library, B cell, Quality of life, Vaccine, Pharmaceutical industry

The research company Geoscells has directed all efforts to achieve victory over one of the most terrible diseases.

Key Points: 
  • The research company Geoscells has directed all efforts to achieve victory over one of the most terrible diseases.
  • "The highly transformative properties of stem cells can be redirected to cancer cells through phenotypic or genetic changes.
  • Further research led to the conclusion that ionotropic glutamate receptors may act as a universal negative marker of cancer stem cells.
  • Laying the foundation for a definitive solution to cancer treatment, research company Geoscells has created an interdisciplinary platform, geoscells.com , to maximize the potential of cancer stem cells.